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Abstract 1 
Background: Although a large number of randomized controlled trials (RCTs) have 2 
examined the impact of the n-3 (ω-3) fatty acids EPA (20:5n-3) and DHA (22:6n-3) on blood 3 
pressure and vascular function, the majority have used doses of EPA+DHA of > 3 g per d, 4 
which are unlikely to be achieved by diet manipulation.  5 
Objective: The objective was to examine, using a retrospective analysis from a multi-center 6 
RCT, the impact of recommended, dietary achievable EPA+DHA intakes on systolic and 7 
diastolic blood pressure and microvascular function in UK adults.  8 
Design: Healthy men and women (n = 312) completed a double-blind, placebo-controlled RCT 9 
consuming control oil, or fish oil providing 0.7 g or 1.8 g EPA+DHA per d in random order 10 
each for 8 wk. Fasting blood pressure and microvascular function (using Laser Doppler 11 
Iontophoresis) were assessed and plasma collected for the quantification of markers of vascular 12 
function. Participants were retrospectively genotyped for the eNOS rs1799983 variant. 13 
Results: No impact of n-3 fatty acid treatment or any treatment * eNOS genotype interactions 14 
were evident in the group as a whole for any of the clinical or biochemical outcomes. 15 
Assessment of response according to hypertension status at baseline indicated a significant 16 
(P=0.046) fish oil-induced reduction (mean 5 mmHg) in systolic blood pressure specifically 17 
in those with isolated systolic hypertension (n=31). No dose response was observed. 18 
Conclusions: These findings indicate that, in those with isolated systolic hypertension, daily 19 
doses of EPA+DHA as low as 0.7 g bring about clinically meaningful blood pressure 20 
reductions which, at a population level, would be associated with lower cardiovascular 21 
disease risk. Confirmation of findings in an RCT where participants are prospectively 22 
recruited on the basis of blood pressure status is required to draw definite conclusions. 23 
 24 
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Introduction 29 
Current dietary guidelines, predominantly informed  by prospective epidemiological evidence 30 
(1, 2), typically recommend a minimum intake of the marine n-3 (ω-3) fatty acids EPA (C20:5n-31 
3) and DHA (C22:6n-3) of 0.5 g per d for healthy individuals, increasing to 1 g per d for those 32 
with diagnosed cardiovascular disease (CVD) (3, 4). The majority of published randomized 33 
controlled trials (RCTs) establishing the efficacy of EPA+DHA on cardiovascular risk factors 34 
have used daily doses of greater than 3 g per d. Such intakes cannot be achieved through diet 35 
manipulation and require use of concentrated or pharmaceutical grade supplements. Meta-36 
analyses or systematic reviews of available RCTs indicate that such high dose (> 3 g 37 
EPA+DHA per d) n-3 fatty acid supplementation reduces systolic and diastolic blood pressure 38 
(SBP and DBP) by approximately 2-4 mmHg and 1-3 mmHg, respectively (5-8) with 39 
hypertensive individuals being most responsive (5, 7). Less well explored is the impact of 40 
intakes of EPA+DHA up to 2 g per d, and in particular in the 0.5 to 1.0 g per d range (commonly 41 
recommended minimum intakes), which can be achieved through the diet by consuming oily 42 
fish (9), on established CVD risk factors such as blood pressure. 43 
Loss of normal vascular function has an etiological role in hypertension and atherogenesis, and 44 
vascular reactivity of both the coronary and peripheral arteries is highly prognostic of future 45 
clinical events (10). The limited data available from adequately powered RCTs provide 46 
inconsistent evidence to indicate whether EPA+DHA can improve arterial vascular reactivity 47 
and stiffness (11, 12). While some more recent trials have used daily intervention doses in the 48 
1.5-3.0 g EPA+DHA range (12-14), the impact of lower intakes on vascular tone and overall 49 
function is poorly understood. Furthermore, the trials with vascular primary end-points have 50 
been conducted mainly in diabetic or hyperlipidemic subjects. Although at the whole 51 
population level the impact of lower intakes of EPA+DHA on blood pressure and vascular 52 
functions may be modest, clinically relevant changes may occur in more responsive population 53 
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sub-groups. Such sub-groups could be specifically targeted to increase their EPA+DHA intake 54 
in order to gain a health benefit. Here we report the impact of modest n-3 fatty acid doses (0.7 55 
and 1.8 g of EPA+DHA per d) on blood pressure and vascular function in healthy adults and 56 
investigate the influence of sex, baseline EPA+DHA and hypertensive status, and endothelial 57 
nitric oxide synthase (eNOS) genotype on response to n-3 fatty acid treatment. We focused on 58 
the eNOSGlu298Asp polymorphism (rs1799983) because of its reported impact on vascular 59 
function and cardiovascular risk (15) along with a previous observation of an influence of this 60 
variant on the association between vasodilation and plasma EPA+DHA concentrations (16), 61 
and more recently the acute vasodilatory response to EPA+DHA intake (17). 62 
 63 
Methods  64 
Subjects and Study Design   65 
The aim of the FINGEN Study (Glasgow, Newcastle, Reading and Southampton Universities) 66 
was to investigate the responsiveness of a range of established and putative markers of CVD 67 
risk to modest dose fish oil intervention. Participants were prospectively recruited on the basis 68 
of apo E (APOE) genotype, sex and age to ensure equal numbers of APOE2 and APOE4 carriers 69 
and APOE3/E3 homozygotes, males and females and spread of age across the five decades 20-70 
70 y. This stratification was undertaken to provide sufficient group size and hence power to 71 
establish the impact of these variables on response to treatment. Details of the study design and 72 
subject characteristics have been published (18). In brief, healthy subjects (n = 364, aged 18-73 
70 y, BMI 18.5 to 30 kg/m2) were recruited according to defined inclusion/exclusion criteria 74 
(see Supplemental Methods). Blood pressure elevation or anti-hypertensive medication use 75 
was not an exclusion criterion. The study was approved by the local research ethics committees 76 
and all subjects provided informed written consent prior to participation (18). The trial adhered 77 
to the principles of the Declaration of Helsinki. 78 
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 79 
Intervention 80 
The study was a double-blind placebo-controlled, dose-response, cross-over study, consisting 81 
of 3 intervention arms each of 8-wk duration. A wash-out period of 12-wk was observed 82 
between intervention arms (18). During the intervention periods participants consumed in 83 
random order, either 3.2 g of the control oil (CO), 3.2 g fish oil (FO) providing 1.8 g 84 
EPA+DHA/d (1.8FO) or a 50:50 CO:FO blend providing 0.7 g EPA+DHA/d (0.7FO). The 85 
CO was an 80:20 mixture of palm oil and soybean oil. The ratio of DHA to EPA in the FO 86 
was 1.4, which approximates the ratio found in marine sources and therefore in the habitual 87 
diet (19, 20). Additionally, participants consumed a low fat meal (< 10 g fat) the evening 88 
before each assessment visit. 89 
 90 
Blood Pressure and Vascular Measurements 91 
Blood pressure (BP) measurements were taken at rest (≥ 5 min) on the non-dominant arm, 92 
which was elevated to heart level, using an automated BP device (Omron Model 705IT, Milton 93 
Keynes, UK). After measuring the upper arm circumference, an appropriately sized cuff 94 
(pneumatic bag 20% wider than the upper arm circumference) was used. Blood pressure 95 
measurements were taken until two consecutive readings were within 10 mmHg for both 96 
systolic BP (SBP) and diastolic BP (DBP). The average of these two stable readings was used 97 
for data analysis. Measurements were performed by fully trained research staff, in accordance 98 
with a multi-center accepted standard operating procedure.   99 
At two of the intervention sites, Reading and Glasgow (n=177), the vascular reactivity of the 100 
cutaneous microvasculature on the volar aspect of the forearm was determined by Laser 101 
Doppler Iontophoresis (LDI) (21). As vascular reactivity is dependent on ambient temperature 102 
and activity levels, all participants were acclimatized at rest in a temperature controlled room 103 
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for 30 minutes prior to LDI assessment. Sodium nitroprusside (SNP, 1% solution) and 104 
acetylcholine (ACh, 1% solution) were used as endothelial independent and dependent 105 
vasodilators, respectively. SNP and ACh were applied to the iontophoresis chambers on the 106 
forearm and delivered transdermally using an incremental current 0-20 μA. The response of 107 
the dermal circulation was measured by Laser Doppler imaging (Moor Instrument Ltd, 108 
Axminster, UK), whereby a backscattered light which experiences a Doppler shift imparted by 109 
moving red cells in the underlying circulation was collected in a series of 20 scans and used to 110 
determine blood flow. Results are expressed as area under the curve (AUC) or incremental 111 
AUC (IAUC) of the 20 scans recorded or flux according to cumulative charge. 112 
 113 
Biochemical Analysis and Genotyping 114 
Fasting blood was drawn into lithium heparin for assessment of NO availability, endothelin-1 115 
(ET-1), adhesion molecules and phosphatidylcholine (PC) fatty acids, with plasma stored in 116 
individual vials at -80°C. NO and ET-1 are key endothelial-derived vasodilatory and 117 
vasoconstrictive agents, respectively (22, 23). NO is labile and cannot be quantified directly; 118 
therefore plasma levels of nitrite+nitrate, which serve as a biomarker of NO availability, where 119 
determined. Total plasma nitrite+nitrate was measured using a commercial kit (R&D Systems 120 
Europe, Abingdon, UK). ET-1 concentrations were analyzed using a Quantiglow human ET-1 121 
immunoassay kit (R&D Systems Europe, Abingdon, UK). The soluble adhesion molecules 122 
quantified using ELISA, included vascular cell adhesion molecule-1 (VCAM-1), intercellular 123 
adhesion molecule-1 (ICAM-1), P-selectin and E-selectin (all kits sourced from BioSource 124 
Europe, Nivelles, Belgium). These molecules, expressed on the surface of endothelial cells, 125 
modulate leukocyte recruitment into the sub-endothelial space and contribute to a pro-126 
inflammatory state and overall vascular dysfunction (24). The fatty acid composition of the 127 
plasma PC fraction was determined using previously described methods (25), with lipid 128 
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extraction, PC isolation using solid phase extraction, transmethylation and methyl ester 129 
separation by gas phase chromatography being the principal steps involved. eNOS genotype 130 
(rs1799983) was determined using a TaqMan (Assay-on-demand) SNP Genotyping kit 131 
(Applied Biosystems, Warrington, UK). 132 
 133 
Statistical Analysis 134 
A repeated-measures analysis was performed to test for a treatment effect, with baseline values 135 
and period (order of intervention) as covariates. Participants were treated as fixed effects, as 136 
the use of random effect models introduces the potential for cross-level bias (26). No treatment 137 
carry-over effect was evident. Subgroup responses according to sex, eNOS genotype, and tertile 138 
of baseline EPA+DHA status were tested by including an interaction term between the group 139 
and treatment in the model. For the main vascular and blood pressure measures, an additional 140 
analysis was conducted in normotensives (NT) vs. hypertensives ((HT); SBP and DBP of ≥ 141 
140 and/or ≥ 90 mmHg) and normotensives vs. dual HTs ((DHT); SBP and DBP of  ≥ 140 and 142 
≥ 90 mmHg) vs. isolated systolic hypertensives ((SHT); SBP ≥ 140 and DPB < 90 mmHg)(27). 143 
The current analysis represented a retrospective secondary analysis of the FINGEN cohort, 144 
with the primary study end-point, and the basis of the original power calculations, being plasma 145 
triglycerides and LDL-cholesterol. The inclusion of 312 subjects in a cross-over design, 146 
provided > 99% power to detect a 6 mmHg reduction in SBP and a 4 mmHg reduction in DBP 147 
between any two treatments in the group as a whole. All analyses were conducted using SAS 148 
Version 9.1 (Cary, US) and SPSS Version 15 (Chicago, US), and P<0.05 was considered to 149 
indicate statistical significance. 150 
 151 
Results 152 
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A total of 312 subjects, including 163 females and 149 males, completed the study (the 153 
CONSORT flow diagram is Supplemental Figure 1 (18)). They had a mean  SD age of 45.0 154 
 13.0 years and BMI of 25.2   3.4 kg/m2, and 6% of subjects were taking anti-hypertensive 155 
medication. 156 
Expressed as absolute % of total fatty acids relative to the control oil, 0.7FO and 1.8FO 157 
increased plasma PC EPA by 1.3 and 2.2 respectively, with increases of 2.1 and 2.5 for DHA 158 
(Table 1, all P<0.001). As we have reported previously (18), a significant sex * treatment 159 
interaction was evident with greater enrichment of PC EPA+DHA in females than in males, 160 
possibly attributable to the higher n-3 fatty acid dose per unit body weight. 161 
 For the participants as a whole, the intervention had no effect on BP, vascular function or any 162 
of the biochemical measures included and there was no evidence of any sex * treatment or 163 
baseline EPA+DHA status * treatment interactions (Table 1).  164 
However, a total of 48 subjects were classified as HT; of these 17 were classified as DHT and 165 
31 as SHT (27).  HTs were older and had higher BMI than NTs (both P<0.001) (Table 2). 166 
Mean  SD baseline SBP and DBP (mmHg) of 118.6  14.0 and 73.0  8.5, 156.8  19.1 and 167 
98.4  10.0, and 145.8  10.5 and 81.1   5.4 were found in NTs, DHTs and SHTs, respectively. 168 
A significant treatment * hypertension status interaction was observed (P=0.022) with a 169 
significant reduction in blood pressure following intervention only for those with SHT (Figure 170 
1a). Relative to CO, 0.7FO and 1.8FO resulted in a mean (95% CI) difference of -5.20 (-9.23, 171 
-1.18) and -5.31 (-9.45, -1.18) mmHg in SBP respectively, with no significant differences 172 
between the treatment groups and no treatment * BP status interaction evident for DBP. 173 
HT status was also associated with a differential DHA response (Figure 1b) (P=0.044) with 174 
evidence of greater increases in the SHT group. Older age has been associated with greater n-175 
3 fatty acid accumulation following supplementation (28), so that the greater DHA response in 176 
HTs may reflect the fact that HTs were on average a decade older than the NT group. 177 
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eNOS genotypic distributions were in Hardy-Weinberg equilibrium with the frequency of 178 
Glu298Glu (48%), Glu298Asp (42%), Asp298Asp (10%) being similar to that observed in 179 
previous studies in Caucasians (16, 29). eNOS genotype was not a significant determinant of 180 
BP or vascular measures or of their response to EPA+DHA intervention (Table 3). 181 
 182 
Discussion 183 
Our main finding is that intakes of EPA+DHA achievable through the consumption of two to 184 
three portions of oily fish per wk, or two fish oil capsules per d, reduced SBP by 5 mmHg in 185 
those with SHT. Such BP reduction would be associated with an approximate 20% reduction 186 
in CVD risk in middle age (30).  187 
In the UK and the US about 30% of adults have high blood pressure (defined as being 188 
hypertensive or being treated with anti-hypertensive medications) (31, 32). In those without 189 
relevant co-morbidities the threshold for drug treatment is a sustained SBP ≥ 160 mmHg and/or 190 
a DBP ≥ 100 mg Hg (33). As a result, in the UK, about half of male and a third of female 191 
hypertensives remain untreated despite compelling evidence of continuous associations 192 
between usual blood-pressure values down to 115 mmHg (systolic) and 75 mmHg (diastolic) 193 
and the risks of major cardiovascular diseases (34). Our data suggest that increased long chain 194 
n-3 PUFA intakes (of only 0.7 g per d, providing approximately 0.3 g EPA and 0.4 g of DHA) 195 
may be an effective strategy for BP control in this large population subgroup.  196 
The size effect from supplementation with n-3 fatty acids (5 mmHg) is largely consistent with 197 
that reported in previous meta-analyses with Morris et al. (8), Appel et al. (35), Geleijnse et al. 198 
(6) and Miller et al. (7) observing reductions of SBP in hypertensives of 3.4, 5.5, 4.0, and 4.5 199 
mmHg, respectively. However, importantly, the current RCT used daily intakes of EPA+DHA 200 
which were 40-90% lower than the mean/median intakes of studies reported in these meta-201 
analyses (3-5 g EPA+DHA per d), indicating that in SHT individuals lower doses are sufficient 202 
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to induce a substantial benefit. In the most recent meta-analysis of Miller et al. (7) which 203 
included 70 RCTs with a mean EPA+DHA dose of 3.8 g per d, twenty studies used doses of 204 
fish oil which provided < 2 g EPA+DHA per d. Of these, only two examined response to 205 
treatment in hypertensive subjects (36, 37). Although both these studies reported no significant 206 
impact on SBP, mean reductions of 5 mmHg were evident in both and it seems likely that a 207 
lack of significance in these two previous studies was due to a lack of power, rather than lack 208 
of a real biological impact (these studies had 17 (36) and 23 (37) individuals in the fish oil 209 
groups, respectively).  210 
It is possible that the high DHA: EPA ratio in the supplement may have contributed to the 211 
relatively large effect size in the current study. Previous RCTs which compared the anti-212 
hypertensive action of EPA vs DHA rich supplements indicated a greater effect of the latter 213 
(38, 39). For example in overweight men supplemented for 6 wk, 4 g of DHA per d, but not 214 
EPA, reduced 24 h and d time ambulatory blood pressure (39). Also, consistent with a lack of 215 
dose response previously reported (5, 7) we observed a similar 5 mmHg reduction in SBP 216 
following both n-3 fatty acid supplementation doses, which may indicate that the maximum 217 
physiological impact is already achieved at the lower intake (0.7 g EPA+DHA per d). 218 
Alternatively, the lack of dose response may reflect the only modestly higher plasma DHA 219 
status achieved at the higher level of supplementation, despite a more than doubling of intake, 220 
with 42% and 58% increased plasma DHA following the 0.7FO and 1.8FO, respectively. This 221 
lack of accrual at higher doses may be attributable to the known increase in β-oxidation of DHA 222 
at higher intakes (40).  223 
The anti-hypertensive effects of EPA and DHA are likely to be due to multiple mechanisms 224 
and to include impacts on heart rate and cardiac output along with improved endothelial and 225 
overall vascular function (14, 41-44). Previously reported mechanisms underlying the vascular 226 
effects, include an increased production of EPA and DHA derived vasoactive eicosanoids and 227 
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epoxides, enhanced bioavailability of nitric oxide, and reduced adhesion molecule expression 228 
associated with improved inflammatory status (25, 43, 45, 46). No impact of treatment on 229 
plasma adhesion molecule concentrations was evident in the current study which is consistent 230 
with what has been seen in several other studies using modest doses of EPA+DHA (46, 47) so 231 
that the efficacy of the supplement used in our study is unlikely to be mediated by changes in 232 
adhesion molecule expression in the endothelium.  233 
Furthermore no impact of treatment on (micro) vascular function as determined by LDI was 234 
evident. The cutaneous vasculature represents an accessible and representative vascular bed for 235 
the establishment of treatment effects on vascular function and specifically NO mediated 236 
vasodilation (48). Although an impact of fish oil supplementation on postprandial 237 
microvascular reactivity has been demonstrated by us and others (14, 17, 49), consistent with 238 
the findings of Stirban et al. (14) and Skulas-Ray et al. (50), no effect of chronic EPA+DHA 239 
supplementation on fasting vasodilation was evident in the current study. However, this does 240 
not preclude an impact of treatment on macrovascular function. Large conduit artery (e.g. aorta) 241 
stiffening, associated with elastin fragmentation and neuro-hormonal alterations in the vascular 242 
wall, and the wave-reflection phenomenon, have been identified as being the most important 243 
pathophysiological determinants of age-related increases in SHT and pulse pressure (51, 52). 244 
Carotid-femoral artery pulse wave velocity (cf-PWV), which increases with increasing 245 
stiffness is the gold standard measure of arterial stiffness. In a 2011 meta-analysis, Pase et al. 246 
(41) showed an overall beneficial impact of EPA+DHA on PWV which has been confirmed in 247 
more recent RCTs (42). The impact of modest (< 2 g per d) EPA+DHA intakes on large artery 248 
compliance and stiffness in those with SHT is unknown and further exploration of this is 249 
merited. 250 
Finally, in contrast with a single previous observational study (16) and with an intervention 251 
trial (17), we observed no impact of the eNOS rs1799983 genotype on vascular or NO 252 
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responses. This gene variant, which alters the amino acid at position 298 in the mature protein 253 
(Glu298Asp), has been shown to increase protein cleavage with consequent inactivation of 254 
eNOS (53), and to be associated with reduced circulating NO levels, vascular reactivity and 255 
CVD incidence (15). Lesson et al. (16) observed that this genotype influenced the association 256 
between plasma EPA+DHA status and flow-mediated brachial artery dilatation (FMD), with a 257 
significant association in 298Asp carriers but not in Glu298Glu homozygotes. Using a 258 
prospective recruitment according to eNOS genotype approach, Thompson and co-workers (17) 259 
reported a 2-fold greater EPA+DHA induced postprandial increase in FMD in Asp298Asp 260 
versus Glu298Glu males and females, with the greater LDI responsiveness in Asp homozygotes 261 
evident in females only. Neither study examined the impact of genotype on the BP response to 262 
treatment. In the current study, the lack of overall impact of this gene variant on vascular 263 
function and SBP suggests that the SBP benefits observed may be independent of NO 264 
bioavailability and NO mediated vasodilation. The limited numbers of participants precluded 265 
any analysis being conducted on potential eNOS rs1799983 genotype * treatment interaction 266 
in the SHT group. 267 
The strengths of the current study are the relatively large group size and associated power to 268 
detect subtle BP changes, the cross-over design, the dose response approach, and the use of 269 
dietary achievable EPA+DHA intakes. Limitations include a lack of ambulatory BP data and 270 
the retrospective secondary nature of the analysis, which resulted in relatively small numbers 271 
in the HT groups relative to those in the NT group. Our prospective recruitment approach 272 
ensured a group of UK adults (20-70 y) who were balanced with respect to sex, age and APOE 273 
genotype. This however resulted in a study population which was over-represented for  APOE2 274 
and APOE4 carriers relative to a typical Caucasian population, which comprise 20-25% and 275 
55-60% respectively (54). Carrying an APOE4 allele has been associated with a greater risk of 276 
hypertension (55). Therefore it is possible that the efficacy of intervention in SHT in the 277 
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FINGEN cohort may in part reflect a greater number of APOE4 carriers relative to the general 278 
population; this group was found to be particularly responsive to the triglyceride lowering 279 
impact of n-3 fatty acid intervention (18). However given that there was a roughly equal 280 
distribution of APOE4 genotype in SHTs (42%) and NTs (36%) it is unlikely that APOE4 281 
genotype influenced the responsiveness in the SHT group. 282 
Conclusions: Our data indicate that in those with isolated systolic hypertension, daily doses of 283 
EPA+DHA as low as 0.7 g can bring about clinically meaningful blood pressure reductions. 284 
Full confirmation of findings in an RCT where participants are prospectively recruited on the 285 
basis of BP status is suggested to draw definite conclusions, with the inclusion of a measure of 286 
conduit artery function in order to gain insight into the physiological basis of the hypotensive 287 
response. 288 
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Figure Legends 307 
Figure 1. Effect of hypertension status at baseline on the systolic blood pressure and 308 
plasma DHA response to the control and fish oil interventions (0.7 and 1.8 g EPA+DHA 309 
per d) in healthy adults.  310 
 311 
(A) Systolic blood pressure and (B) Diastolic blood pressure  312 
Data are mean difference with 95% CI, mmHg 313 
Hypertension (HT) status categorized individuals as either normotensive (Normal, n=264, SBP < 140 mmHg 314 
and DBP < 90 mmHg), dual hypertensive (DHT, n=17, SBP ≥ 140 mmHg and DBP ≥ 90 mmHg) or isolated 315 
systolic hypertensive (SHT, n=31, SBP ≥ 140 mmHg and DBP < 90 mmHg). 316 
In repeated measures analysis on end of treatment values, with baseline values and period as co-variates, a 317 
significant treatment * HT status interaction was evident for SBP (P = 0.046) and plasma DHA (P = 0.044).  318 
CO, control oil; 0.7FO, 0.7 g EPA+DHA per d; 1.8FO, 1.8 g EPA+DHA per d   319 
   320 
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Table 1: Vascular and plasma biochemical responses to the control and two doses of fish oil for 8 wk each in healthy adults1  
 
 CO2 
8 wk 
0.7FO2 
8 wk 
1.8FO2 
8 wk 
P, treatment3 P, sex * 
treatment3 
P, HT status4 * 
treatment3 
P, EPA+DHA 
status4 * 
treatment3 
BMI (kg/m2) 25.2  3.41,a 25.4  3.4b 25.3  3.5b 0.006 NS5 NS NS 
DBP, mmHg 75.2  9.2 74.6  9.2 74.9  9.8 NS NS NS NS 
SBP, mmHg 124  15 123  16 123  16 NS NS 0.046 NS 
ACHAUC, flux units 1300  7091 1320  779 1310  671 NS NS NS NS 
SNPAUC, flux units 1500  781 1500  857 1560  834 NS NS NS NS 
        
Plasma PC EPA, % total FA 1.6  0.8a 2.9  1b 3.8  1.2c <0.001 <0.0016 0.08 (NS) NS 
Plasma PC DHA, % total FA 4.3  1.2a 6.2  1.2b 6.8  1.4c <0.001 NS 0.044 NS 
        
Nitrate + nitrite, μM 102  40 104  40 99  38 NS NS NS 0.08 (NS) 
Endothelin-1, pg/ml 0.97  0.51 0.96  0.49 0.93  0.44 NS NS NS NS 
sVCAM-1, ng/ml 1920  952 1830  926 1860  927 NS NS NS NS 
sICAM-1, ng/ml 324  135 315  136 315  122 NS NS NS NS 
sE-Selectin, ng/ml 75.9  39.3 76.9  37.9 76.2  38.2 NS NS NS 0.07 (NS) 
sP-Selectin, ng/ml 67.4  64.5 68.8  76.2 68.5  67.1 NS NS NS NS 
1Data are mean  SD, n=312 except for SNPAUC and ACHAUC where n = 161.  
2CO- control oil; 0.7FO- 0.7 g EPA+DHA per d; 1.8FO- 1.8 g EPA+DHA per d, 
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3To test for a treatment effect a repeated measures analysis was carried out, with baseline values and period as covariates. In order to establish response to treatment according to sex, HT 
and EPA+DHA status at baseline an interaction term between the group and treatment was included in the model, 
4Hypertension (HT) status categorizes individuals as either normotensive (n=264, SBP < 140 mmHg and DBP < 90 mmHg), dual hypertensive (n=17, SBP ≥ 140 mmHg and DBP ≥ 90 mmHg) or 
isolated systolic hypertensive (n=31, SBP ≥ 140 mmHg and DBP < 90 mmHg): 4EPA+DHA status categorizes individuals in tertiles (T) according to EPA+DHA as a % of total plasma 
phosphatidylcholine fatty acids, 
5NS is non-significant, P > 0.05, 
6Males had significant differences relative to females for both low CO vs 0.7FO and CO vs 1.8FO, but not significantly different between 0.7FO and 1.8FO 
a,b,c Labelled means in a row without a common letter differ, P < 0.05, 
Abbreviations: ACHAUC- the vasodilatory response to acetylcholine, DBP-diastolic blood pressure, DPA- docosapentaenoic acid, FA- fatty acids, HT- hypertension, ICAM- intercellular adhesion 
molecule, PC- phosphatidylcholine, SBP-systolic blood pressure, SNPAUC- the vasodilatory response to sodium nitroprusside, VCAM- vascular cell adhesion molecule. 
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Table 2: Baseline characteristics of the cohort according to blood pressure status in healthy adults1 
 NT (n=264)2 
 
DHT (n=17)2 SHT (n=31)2 P3 
Age, y 43.7  12.81,a 54.0  5.5b 53.4  13.0b <0.001 
BMI, kg/m2 25.1  4.8a 27.1  3.1b 27.3  2.7b 0.011 
Female/male 150/114 3/17 10/21 <0.001 
     
DBP, mmHg 73.0  8.5a 98.4  10.0c 81.1  5.4b <0.001 
SBP, mmHg 119  14a 157  19c 146  11b <0.001 
ACHAUC, flux units 1530  1050 1020  413 1350  573 NS4 
SNPAUC, flux units 1720  1064 1390  452 1440  558 NS 
     
Plasma PC EPA, % total FA 1.6  0.8 1.8  0.9 1.5  0.7 NS 
Plasma PC DHA, % total FA 4.4  1.2 4.6  1.4 4.2  1.3 NS 
     
Nitrate + nitrite, μM 98  41 107  46 104  35 NS 
Endothelin 1, pg/ml 0.95  0.49 1.03  0.52 1.09  0.59 NS 
sVCAM-1, ng/ml 1870  933 1780  849 1910  851 NS 
sICAM-1, ng/ml 302  132 330  105 330  142 NS 
sE-Selectin, ng/ml 72.2  40.0 79.2  41.4 80.3  27.2 NS 
sP-Selectin, ng/ml 64.4  71.4 72.6  41.4 73.4  102.9 NS 
1Data are mean  SD, n= 264, 17 and 31 for NT, DHT and SHT respectively for all variables apart from ACHAUC and SNP AUC 
where n= 142, 6 and 13 for NT, DHT and SHT respectively, 
2Normotensive (NT), SBP < 140 mmHg and DBP < 90 mmHg; Dual hypertensive (DHT), SBP ≥ 140 mmHg and DBP ≥ 90 
mmHg; Isolated systolic hypertensive (SHT), SBP ≥ 140 mmHg and DBP < 90 mmHg, 
3Inter-group differences were analyzed by 1-way ANOVA,  
4NS is non-significant, P > 0.05, 
a,b,c Labelled means in a row without a common letter differ, P < 0.05, 
Abbreviations: ACHAUC- the vasodilatory response to acetylcholine, DBP-diastolic blood pressure, DPA- docosapentaenoic 
acid, FA- fatty acids, ICAM- intercellular adhesion molecule, PC- phosphatidylcholine, SBP-systolic blood pressure, SNPAUC- 
the vasodilatory response to sodium nitroprusside, VCAM- vascular cell adhesion molecule. 
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Table 3: Vascular and plasma nitrate plus nitrite responses to the control and two doses of fish oil 
for 8 wk each in healthy adults, according to eNOS genotype  
 CO2 
8 wk 
0.7FO2 
8 wk 
1.8FO2 
8 wk 
P, treatment 
*eNOS genotype3 
SBP, mmHg 
-Glu298Glu 
-Glu298Asp 
-Asp298Asp 
 
123   161 
123   15 
127  14 
 
124   16 
122   16 
126   15 
 
124   17 
122   16 
126   15 
NS4 
DBP, mmHg 
-Glu298Glu 
-Glu298Asp 
-Asp298Asp 
 
75.0  9.1 
74.6  9.5 
78.7  7.9 
 
74.7   9.3 
73.9   9.1 
76.9   8.6 
 
74.8   9.5 
74.1   10.2 
78.7   9.2 
NS 
ACHAUC, flux units 
-Glu298Glu6 
-Glu298Asp 
-Asp298Asp 
 
1290  656 
1370  791 
1130  567 
 
1210   634 
1380   895 
1610   818 
 
1330   669 
1260   656 
1400   848 
NS 
SNPAUC, flux units 
-Glu298Glu 
-Glu298Asp 
-Asp298Asp 
 
1470  776 
1600  833 
1270  568 
 
1390   738 
1590   984 
1660   857 
 
1590   860 
1470   811 
1690   903 
NS 
Nitrate + nitrite, 
μM 
-Glu298Glu6 
-Glu298Asp 
-Asp298Asp 
 
101   42 
104  39 
101  37 
 
102   40 
105   39 
96   35 
 
100   43 
97   32 
102   36 
NS 
1Data are mean  SD, Glu298Glu, n=146, Glu298Asp, n=127 and Asp298Asp, n=30 for SBP, DBP and nitrate and nitrite; 
Glu298Glu, n=73 Glu298Asp, n=69 and Asp298Asp, n=15 for ACHAUC and SNPAUC,  
2CO- control oil; 0.7FO- 0.7 g EPA+DHA per d; 1.8FO- 1.8 g EPA+DHA per d 
3To test for a treatment effect a repeated measures analysis was carried out, with baseline values and period as covariates. 
In order to establish response to treatment according to eNOS genotype an interaction term was included in the model.  
4NS is non-significant, P > 0.05, 
Abbreviations: ACHAUC- the vasodilatory response to acetylcholine, DBP-diastolic blood pressure, SBP-systolic blood 
pressure, SNPAUC- the vasodilatory response to sodium nitroprusside.  
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ONLINE SUPPORTING MATERIAL 
 
Supplemental Methods: FINGEN INCLUSION/EXCLUSION CRITERIA 
 
Inclusion criteria 
 Aged 20 to 70 y 
 APO E2/E2, E2/E3, E3/E3, E3/E4, E4/E4 
 Male or female 
 BMI 18.5-32 kg/m2 
 total cholesterol < 8.0 mM 
 TG < 3.0 mM  
 glucose < 6.8 mM. 
 
Exclusion criteria 
 APO E2/E4 
 suffered a myocardial infarction (MI) in the previous 2 years  
 chronic inflammatory conditions including inflammatory bowel disease (IBD) and 
irritable bowel syndrome (IBS) 
 diabetes or other endocrine disorders  
 pregnant, lactating or planning a pregnancy in the next 12 months 
 kidney or liver function markers outside the normal range  
 iron deficient (hemoglobin < 12 g/dL men, < 11 g/dL women)  
 on hypolipidemic medication 
 on anti-inflammatory medication  
 use of asthmatic inhalers > twice per month 
 use of aspirin > once per wk 
 on any fatty acid supplement 
For individuals on fatty acid supplements who are willing to stop taking their 
supplements, a wash-out period of 8 wk was required 
 consuming high doses of antioxidant vitamins (A, C, E, -carotene). Maximum permitted 
intake: 800 g/d Vitamin A, 60 mg/d Vitamin C, 10 mg/d Vitamin E and 400 g/d -
carotene  
For individuals on greater than the permitted dose of antioxidant vitamins and who are 
willing to stop taking their supplements, a wash-out period of 4 wk was required 
 consuming more than one serving (150 g) of oily fish per wk, which includes herring, 
mackerel, kippers, pilchards, sardines, salmon, trout, tuna (fresh), crabmeat or marlin. 
Canned tuna is permitted as it contains only minor amounts of long chain n-3 PUFAs 
 trained or endurance athletes or those who participate in more than 3 planned periods of 
exercise per wk 
 planning to lose weight by joining a weight reduction class or following an organized 
weight reducing regimen (e.g. the Slimfast Plan, Atkins Diet etc.) 
 use of Benecol or Flora Pro-Active spreads. 
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Supplemental Figure 1: Study CONSORT Flow Diagram 
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